AMGN

Amgen Inc (AMGN) is the lead sponsor of 99 active clinical trials listed on ClinicalTrials.gov^[5], including 47 Phase 3^[1], 20 Phase 2^[2], 30 Phase 1^[3], 6 Phase 4^[4].

Trial NCT03836040^[6] evaluates Erenumab Dose 1 in Migraine with a target enrollment of 457 participants. Trial NCT04524273^[7] evaluates inebilizumab in Myasthenia Gravis with a target enrollment of 238 participants. Trial NCT03633708^[8] evaluates Etelcalcetide in Secondary Hyperparathyroidism with a target enrollment of 56 participants.

AMGN has 10 Form 4 insider filings recorded at the SEC in the past 30 days^[9].